FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887281271> ?p ?o ?g. }

• W2887281271 abstract "Cytokine-based cancer therapies have attracted a great deal of attention in recent years. Unfortunately, resistance to treatment limits the efficacy of these therapeutics. Therefore, the aim of our study was to explore the mechanism of IL-2-based therapy for hepatocellular carcinoma in an attempt to increase the efficiency of this treatment option. HepG2 cells were treated with IL-2. Then, siRNA against TZA was used to transfected into HepG2 cells. Cellular apoptosis was measured via MTT assay, TUNEL assay and caspase-3 activity. Cellular proliferation was evaluated via EdU assay and western blotting. Cellular migration was detected via Transwell assay. Mitochondrial function was monitored by mitochondrial potential analysis, ROS staining, immunofluorescence and western blotting. Pathway blocker and activator were used to establish the role of JNK/F-actin/mitochondrial fission signaling pathway in HepG2 cells stress response. Our study found that IL-2 treatment significantly reduced the viability, mobility and proliferation of HepG2 cells in vitro. We also demonstrated that IL-2 treatment was accompanied by an increase in the expression of transcriptional co-activator with PDZ-binding motif (TAZ). Interestingly, genetic ablation of TAZ in the presence of IL-2 further promoted apoptosis, inhibited mobility, and arrested proliferation in HepG2 cells. At the molecular level, IL-2 administration activated excessive mitochondrial fission via the JNK/F-actin pathway; these effects were further enhanced by TAZ deletion. Mechanistically, TAZ knockdown further increased the expression of mitochondrial fission-related proteins such as Drp1, Mff and Fis. The augmented mitochondrial fission stimulated ROS overproduction, mediated redox imbalance, interrupted mitochondrial energy generation, reduced mitochondrial membrane potential, promoted leakage of the pro-apoptotic molecule cyt-c into the nucleus, and initiated caspase-9-related mitochondrial death. Further, we demonstrated that the anti-proliferative and anti-metastatic effects of IL-2 in HepG2 cells were enhanced by TAZ deletion, suggesting that IL-2 sensitizes HepG2 cells to IL-2-based cytokine therapy. However, JNK/F-actin pathway blockade could abrogate the inhibitory effects of TAZ deletion on HepG2 migration, proliferation and survival. Taken together, our data indicate that the anti-tumor effects of IL-2-based therapies may be enhanced by TAZ deletion in a JNK/F-actin pathway-dependent manner. This finding provides a novel combinatorial therapeutic approach for treating hepatocellular carcinoma that might significantly increase the efficacy of cytokine-based therapies in a clinical setting." @default.
• W2887281271 created "2018-08-22" @default.
• W2887281271 creator A5009105017 @default.
• W2887281271 creator A5032564609 @default.
• W2887281271 creator A5046511818 @default.
• W2887281271 creator A5046659345 @default.
• W2887281271 creator A5057055806 @default.
• W2887281271 creator A5062045949 @default.
• W2887281271 creator A5063795630 @default.
• W2887281271 creator A5084950012 @default.
• W2887281271 creator A5085609481 @default.
• W2887281271 date "2018-08-14" @default.
• W2887281271 modified "2023-10-15" @default.
• W2887281271 title "TAZ inhibition promotes IL-2-induced apoptosis of hepatocellular carcinoma cells by activating the JNK/F-actin/mitochondrial fission pathway" @default.
• W2887281271 cites W1987516241 @default.
• W2887281271 cites W2009219530 @default.
• W2887281271 cites W2033255923 @default.
• W2887281271 cites W2108473659 @default.
• W2887281271 cites W2183712579 @default.
• W2887281271 cites W2343918127 @default.
• W2887281271 cites W2527602686 @default.
• W2887281271 cites W2547342796 @default.
• W2887281271 cites W2551312221 @default.
• W2887281271 cites W2556746616 @default.
• W2887281271 cites W2560966368 @default.
• W2887281271 cites W2566543319 @default.
• W2887281271 cites W2568811756 @default.
• W2887281271 cites W2577830243 @default.
• W2887281271 cites W2581916759 @default.
• W2887281271 cites W2582957437 @default.
• W2887281271 cites W2583414336 @default.
• W2887281271 cites W2586141836 @default.
• W2887281271 cites W2586442417 @default.
• W2887281271 cites W2586706543 @default.
• W2887281271 cites W2587302795 @default.
• W2887281271 cites W2587319550 @default.
• W2887281271 cites W2587833196 @default.
• W2887281271 cites W2588049838 @default.
• W2887281271 cites W2590024745 @default.
• W2887281271 cites W2591395115 @default.
• W2887281271 cites W2593345096 @default.
• W2887281271 cites W2593497446 @default.
• W2887281271 cites W2593574515 @default.
• W2887281271 cites W2596407801 @default.
• W2887281271 cites W2602260596 @default.
• W2887281271 cites W2605501320 @default.
• W2887281271 cites W2612061536 @default.
• W2887281271 cites W2612349673 @default.
• W2887281271 cites W2616465646 @default.
• W2887281271 cites W2617527111 @default.
• W2887281271 cites W2620964728 @default.
• W2887281271 cites W2626836216 @default.
• W2887281271 cites W2731724235 @default.
• W2887281271 cites W2733292600 @default.
• W2887281271 cites W2735250338 @default.
• W2887281271 cites W2741393094 @default.
• W2887281271 cites W2747826704 @default.
• W2887281271 cites W2763698944 @default.
• W2887281271 cites W2766027236 @default.
• W2887281271 cites W2766552257 @default.
• W2887281271 cites W2768024671 @default.
• W2887281271 cites W2768365998 @default.
• W2887281271 cites W2769667901 @default.
• W2887281271 cites W2771543040 @default.
• W2887281271 cites W2773489190 @default.
• W2887281271 cites W2773523113 @default.
• W2887281271 cites W2775187110 @default.
• W2887281271 cites W2777514005 @default.
• W2887281271 cites W2784192559 @default.
• W2887281271 cites W2786307681 @default.
• W2887281271 cites W2789860518 @default.
• W2887281271 cites W2790553322 @default.
• W2887281271 cites W2791574216 @default.
• W2887281271 cites W2794268420 @default.
• W2887281271 cites W2794429703 @default.
• W2887281271 cites W2794686887 @default.
• W2887281271 cites W2797819071 @default.
• W2887281271 cites W2801343489 @default.
• W2887281271 cites W2802650264 @default.
• W2887281271 cites W2803454423 @default.
• W2887281271 cites W2806263581 @default.
• W2887281271 cites W2884686428 @default.
• W2887281271 cites W3098089436 @default.
• W2887281271 cites W3144477591 @default.
• W2887281271 doi "https://doi.org/10.1186/s12935-018-0615-y" @default.
• W2887281271 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6092825" @default.
• W2887281271 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30127666" @default.
• W2887281271 hasPublicationYear "2018" @default.
• W2887281271 type Work @default.
• W2887281271 sameAs 2887281271 @default.
• W2887281271 citedByCount "13" @default.
• W2887281271 countsByYear W28872812712018 @default.
• W2887281271 countsByYear W28872812712019 @default.
• W2887281271 countsByYear W28872812712020 @default.
• W2887281271 countsByYear W28872812712021 @default.
• W2887281271 countsByYear W28872812712023 @default.
• W2887281271 crossrefType "journal-article" @default.
• W2887281271 hasAuthorship W2887281271A5009105017 @default.
• W2887281271 hasAuthorship W2887281271A5032564609 @default.
• W2887281271 hasAuthorship W2887281271A5046511818 @default.

• next